TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Intensity Trial (EXCITE): A Randomized Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer
Brief Summary: The purpose of this study is to compare the effects of 3 different approaches to exercise training in women with early stage breast cancer who have completed all primary treatments (except hormone therapy, if appropriate). Prior research in women with early stage breast cancer has shown that some treatments may have an adverse impact on physical fitness levels leading to feelings of fatigue and poor quality of life. Supervised exercise training has been shown to reduce some of these side-effects. However, all the exercise programs have followed essentially the same approach. This study is designed to see if a different approach to exercise training is more effective than the conventional approach currently in use.


Options:
A: Arm Label: Patients Pre and Post-chemotherapy; Type: N/A; Interventions: N/A
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise programme | Arm Label: No Exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise programme; Assigned to Arm(s): Exercise
C: Arm Label: Linear Aerobic Training; Type: EXPERIMENTAL; Interventions: Behavioral: Linear Aerobic Training, Other: Cardiopulmonary exercise test (CPET), Other: Blood draws | Arm Label: Nonlinear Aerobic Training; Type: EXPERIMENTAL; Interventions: Behavioral: Nonlinear Aerobic Training, Other: Cardiopulmonary exercise test (CPET), Other: Blood draws | Arm Label: Progressive Stretching Group (Attention control); Type: EXPERIMENTAL; Interventions: Behavioral: Progressive Stretching, Other: Cardiopulmonary exercise test (CPET), Other: Blood draws | Intervention Type: BEHAVIORAL; Name: Linear Aerobic Training; Assigned to Arm(s): Linear Aerobic Training | Intervention Type: BEHAVIORAL; Name: Nonlinear Aerobic Training; Assigned to Arm(s): Nonlinear Aerobic Training | Intervention Type: BEHAVIORAL; Name: Progressive Stretching; Assigned to Arm(s): Progressive Stretching Group (Attention control) | Intervention Type: OTHER; Name: Cardiopulmonary exercise test (CPET); Assigned to Arm(s): Linear Aerobic Training, Nonlinear Aerobic Training, Progressive Stretching Group (Attention control) | Intervention Type: OTHER; Name: Blood draws; Assigned to Arm(s): Linear Aerobic Training, Nonlinear Aerobic Training, Progressive Stretching Group (Attention control)
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional resistance training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Whole body vibration resistance training | Intervention Type: OTHER; Name: Conventional resistance training; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Whole body vibration resistance training; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension
Brief Summary: The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver. FBS0701 is a medication taken by mouth that causes the body to get rid of iron. Iron chelators are used in patients with β-thalassemia and other forms of anemia who experience iron overload - iron increases in the body as a result of regularly required blood transfusions. Patients who qualify will be randomized to receive one of two doses of FBS0701 for up to 24 weeks (6 months) with a total study duration of up to 33 weeks. These patients will be eligible to participate in a dosing extension for up to 72 weeks. The maximum duration of dosing will be up to 96 weeks. The safety of patients will be monitored frequently during the study by physical exams, ECGs, and blood tests. To assess the amount of iron in the liver and heart, each patient must undergo 6 MRI scans during the study. Patients will not need to stay in the hospital for this study but will need to visit the outpatient clinic up to 28 times over the 96 week period. Patients currently taking an iron chelator will be required to stop for a total of up to 26 weeks. The results of this study will help to determine if FBS0701 may be effective as an iron chelator.


Options:
A: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
C: Arm Label: Thalassemia; Type: N/A; Interventions: N/A
D: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension
Brief Summary: The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver. FBS0701 is a medication taken by mouth that causes the body to get rid of iron. Iron chelators are used in patients with β-thalassemia and other forms of anemia who experience iron overload - iron increases in the body as a result of regularly required blood transfusions. Patients who qualify will be randomized to receive one of two doses of FBS0701 for up to 24 weeks (6 months) with a total study duration of up to 33 weeks. These patients will be eligible to participate in a dosing extension for up to 72 weeks. The maximum duration of dosing will be up to 96 weeks. The safety of patients will be monitored frequently during the study by physical exams, ECGs, and blood tests. To assess the amount of iron in the liver and heart, each patient must undergo 6 MRI scans during the study. Patients will not need to stay in the hospital for this study but will need to visit the outpatient clinic up to 28 times over the 96 week period. Patients currently taking an iron chelator will be required to stop for a total of up to 26 weeks. The results of this study will help to determine if FBS0701 may be effective as an iron chelator.


Options:
A: Arm Label: Starch pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amlodipine | Arm Label: Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine, Starch pill
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
C: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
D: Arm Label: Thalassemia; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care. A Pragmatic Cluster Randomised Controlled Trial in Primary Health Care
Brief Summary: A huge challenge in type 2-diabetes care is how to motivate patients towards health behaviour changes. In Denmark, the tendency is that nurses in general practice provide a large part of type 2 diabetes care.

Observational studies support Self-determination Theory by finding autonomous motivation and perceived competence associated with improved HbA1c-levels in patients with type 2 diabetes. Hence, research is needed to develop and test interventions that are autonomy supportive.

Aim To develop a training course for practice-nurses in autonomy support in patients with type 2 diabetes, and to evaluate the effect on patient outcomes.

Methods The development of the intervention was based on literature research and expert meetings. The intervention is evaluated in a cluster randomised controlled trial with 40 Danish general practices,

* where nurses, before enrolment in the study, provided consultations to patients with type 2 diabetes,
* and about 2500 patients with type 2 diabetes, identified in a Diabetes Database.

The patients will be followed 15 months from nurse-participation in the course. Data will be obtained from registers and patient-questionnaires. The hypothesis is that patients with type 2 diabetes regardless of education level, age, and gender will benefit from the intervention.


Options:
A: Arm Label: Medical group visits; Type: EXPERIMENTAL; Interventions: Other: Diabetes Group Management Visits | Arm Label: Treatment as Usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes Group Management Visits; Assigned to Arm(s): Medical group visits
B: Arm Label: Pharmacist management; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical pharmacist-based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical pharmacist-based intervention; Assigned to Arm(s): Pharmacist management
C: Arm Label: close follow-up by nurse; Type: N/A; Interventions: Behavioral: Secondary prevention intervention trial | Arm Label: standard follow up; Type: N/A; Interventions: Behavioral: standard follow up | Intervention Type: BEHAVIORAL; Name: Secondary prevention intervention trial; Assigned to Arm(s): close follow-up by nurse | Intervention Type: BEHAVIORAL; Name: standard follow up; Assigned to Arm(s): standard follow up
D: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care. A Pragmatic Cluster Randomised Controlled Trial in Primary Health Care
Brief Summary: A huge challenge in type 2-diabetes care is how to motivate patients towards health behaviour changes. In Denmark, the tendency is that nurses in general practice provide a large part of type 2 diabetes care.

Observational studies support Self-determination Theory by finding autonomous motivation and perceived competence associated with improved HbA1c-levels in patients with type 2 diabetes. Hence, research is needed to develop and test interventions that are autonomy supportive.

Aim To develop a training course for practice-nurses in autonomy support in patients with type 2 diabetes, and to evaluate the effect on patient outcomes.

Methods The development of the intervention was based on literature research and expert meetings. The intervention is evaluated in a cluster randomised controlled trial with 40 Danish general practices,

* where nurses, before enrolment in the study, provided consultations to patients with type 2 diabetes,
* and about 2500 patients with type 2 diabetes, identified in a Diabetes Database.

The patients will be followed 15 months from nurse-participation in the course. Data will be obtained from registers and patient-questionnaires. The hypothesis is that patients with type 2 diabetes regardless of education level, age, and gender will benefit from the intervention.


Options:
A: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit
B: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Workshops and focus group meetings | Arm Label: Control - no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Workshops and focus group meetings; Assigned to Arm(s): Educational intervention
C: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical, Randomized, Comparative, Non-blinded Study on the Effect of Bladdertraining in Groups Compared to Individual Bladdertraining for Female Patients With Overactive Bladder.
Brief Summary: Hypothesis:the effect of bladdertraining in groups for patients with OAB (overactive bladder syndrome) equals the effect of bladdertraining individually for patients with overactive bladder.

The effect of the training is measured in a 3 dimensional scope by the means of 3 primary outcome measures used in the statistical evaluation. Symptoms of OAB (either (1)urgencyepisodes or (2)urgencyincontinence) and (3)quality of life (VAS score).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2
B: Arm Label: Group Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Group Behavioral Treatment | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group Behavioral Treatment; Assigned to Arm(s): Group Behavioral Treatment
C: Arm Label: bladdertraining group; Type: EXPERIMENTAL; Interventions: Behavioral: bladdertraining in groups | Arm Label: bladdertraining individually; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: bladdertraining individually | Intervention Type: BEHAVIORAL; Name: bladdertraining in groups; Assigned to Arm(s): bladdertraining group | Intervention Type: BEHAVIORAL; Name: bladdertraining individually; Assigned to Arm(s): bladdertraining individually
D: Arm Label: MyHealthebladder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MyHealtheBladder | Arm Label: VA Video Connect; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: VA Video Connect | Intervention Type: BEHAVIORAL; Name: VA Video Connect; Assigned to Arm(s): VA Video Connect | Intervention Type: BEHAVIORAL; Name: MyHealtheBladder; Assigned to Arm(s): MyHealthebladder

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical, Randomized, Comparative, Non-blinded Study on the Effect of Bladdertraining in Groups Compared to Individual Bladdertraining for Female Patients With Overactive Bladder.
Brief Summary: Hypothesis:the effect of bladdertraining in groups for patients with OAB (overactive bladder syndrome) equals the effect of bladdertraining individually for patients with overactive bladder.

The effect of the training is measured in a 3 dimensional scope by the means of 3 primary outcome measures used in the statistical evaluation. Symptoms of OAB (either (1)urgencyepisodes or (2)urgencyincontinence) and (3)quality of life (VAS score).


Options:
A: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
C: Arm Label: Total Control Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Total Control Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Total Control Program; Assigned to Arm(s): Total Control Program
D: Arm Label: bladdertraining group; Type: EXPERIMENTAL; Interventions: Behavioral: bladdertraining in groups | Arm Label: bladdertraining individually; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: bladdertraining individually | Intervention Type: BEHAVIORAL; Name: bladdertraining in groups; Assigned to Arm(s): bladdertraining group | Intervention Type: BEHAVIORAL; Name: bladdertraining individually; Assigned to Arm(s): bladdertraining individually

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Treatment of Overactive Bladder in Men
Brief Summary: The primary purpose of this project is to evaluate the effectiveness of behavioral treatment compared to standard drug therapy for symptoms of OAB in male veterans.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tolterodine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: bladder training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor muscle training | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor rehabilitation | Intervention Type: PROCEDURE; Name: tolterodine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: bladder training; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: pelvic floor muscle training; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: pelvic floor rehabilitation; Assigned to Arm(s): 4
B: Arm Label: 1 Bladder Health Class; Type: OTHER; Interventions: Behavioral: Bladder Health Class | Arm Label: 2 Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bladder Health Class; Assigned to Arm(s): 1 Bladder Health Class
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Darifenacin | Arm Label: 2; Type: OTHER; Interventions: Drug: Darifenacin, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Darifenacin; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 2
D: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Treatment of Overactive Bladder in Men
Brief Summary: The primary purpose of this project is to evaluate the effectiveness of behavioral treatment compared to standard drug therapy for symptoms of OAB in male veterans.


Options:
A: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy
B: Arm Label: Fesoterodine (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Double-Blind)
C: Arm Label: Botox A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A (Botox A®) | Arm Label: Standardized Anticholinergic Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin 5mg, Drug: Solifenacin 10mg, Drug: Trospium chloride | Intervention Type: DRUG; Name: Botulinum toxin A (Botox A®); Assigned to Arm(s): Botox A | Intervention Type: DRUG; Name: Solifenacin 5mg; Assigned to Arm(s): Standardized Anticholinergic Regimen | Intervention Type: DRUG; Name: Solifenacin 10mg; Assigned to Arm(s): Standardized Anticholinergic Regimen | Intervention Type: DRUG; Name: Trospium chloride; Assigned to Arm(s): Standardized Anticholinergic Regimen
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): 3

Answer: A